Egg phospholipids

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Egg phospholipids
Accession Number
DB14233
Type
Biotech
Groups
Approved, Experimental, Investigational
Description

Egg phospholipids are primarily a mixture of naturally occurring phospholipids which are isolated from the egg yolk. Egg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.

Synonyms
  • Egg lecithin
  • Egg lecithin component of endolipide
  • Egg oil lecithin
  • Egg oil phospholipids
  • Egg phosphatides
  • Egg phospholipid
  • Egg phospholipids
  • Egg yolk lecithin
  • Egg yolk lecithins
  • Egg yolk phosphatides
  • Egg yolk phospholipids
  • Endolipide component egg lecithin
  • Lecithins, egg yolk
  • Phospholipids egg
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10% Travamulsion Liq IVEgg phospholipids (1.2 g) + Soybean oil (10 g)LiquidIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312015-08-05Canada
20% Travamulsion Liq IVEgg phospholipids (1.2 g) + Soybean oil (20 g)LiquidIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312015-08-05Canada
Liposyn IIEgg phospholipids (1.2 g/100mL) + Safflower oil (10 g/100mL) + Soybean oil (10 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-08-272011-02-01Us
Liposyn IIEgg phospholipids (1.2 g/100mL) + Safflower oil (5 g/100mL) + Soybean oil (5 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-08-272011-02-01Us
Liposyn II 10%Egg phospholipids (0.9 %) + Safflower oil (5 %) + Soybean oil (5 %)EmulsionIntravenousHospira Healthcare Ulc1987-12-312014-08-01Canada
Liposyn II 20%Egg phospholipids (1.2 %) + Safflower oil (10 %) + Soybean oil (10 %)EmulsionIntravenousHospira Healthcare Ulc1987-12-312014-08-01Canada
Liposyn II Inj 10%Egg phospholipids (700 mg) + Safflower oil (5.0 g) + Soybean oil (5.0 g)EmulsionIntravenousHospira Healthcare Ulc1992-01-012014-08-01Canada
Liposyn IIIEgg phospholipids (1.2 g/100mL) + Glycerin (2.5 g/100mL) + Soybean oil (20 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-09-252011-07-01Us
Liposyn IIIEgg phospholipids (1.2 g/100mL) + Glycerin (2.5 g/100mL) + Soybean oil (10 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-09-242011-07-01Us
Liposyn IIIEgg phospholipids (1.8 g/100mL) + Glycerin (2.5 g/100mL) + Soybean oil (30 g/100mL)Injection, emulsionIntravenousHospira, Inc.2011-05-012011-06-01Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PuralorEgg phospholipids (42.5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine (5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine (2.5 mg/1) + Acetylcysteine amide (5 mg/1) + Ascorbic acid (25 mg/1) + Cholecalciferol (100 [iU]/1) + Citric acid (1.6 mg/1) + Cobamamide (2 mg/1) + Folic acid (42.5 mg/1) + Gastric intrinsic factor (2.5 mg/1) + Magnesium L-threonate (2.5 mg/1) + Leucovorin (3 mg/1) + Levomefolic acid (0.4 mg/1) + Magnesium glycinate (1 mg/1) + Niacin (0.5 mg/1) + Pantethine (2.5 mg/1) + Papain (20 mg/1) + Riboflavin (0.5 mg/1) + Sodium citrate (0.8 mg/1) + Thiamine chloride (0.5 mg/1)Tablet, chewableOralCenturion Labs2014-01-012017-09-20Us
Categories
Not Available
UNII
1Z74184RGV
CAS number
93685-90-6

Pharmacology

Indication

For use as a source of calories for patients requiring parenteral nutrition.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHippel-Lindau Disease / Renal Cancers1
Not AvailableTerminatedPreventionHypertriglyceridemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous
EmulsionIntravenous
Injection, emulsionIntravenous
CapsuleOral
Tablet, chewableOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9717852No2017-08-012033-04-08Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 04, 2018 20:37 / Updated on November 02, 2019 03:22